Inhibition of VEGF-C is seen as a promising approach to restricting the blood and nutrient supply that supports tumor growth.

Vegenics licensed from CoGenesys exclusive, worldwide rights to human mAbs that target vascular endothelial growth factor-C (VEGF-C). VEGF-C is believed to play an important role in promoting the formation of new blood vessels and the maintenance of existing blood vessels.

“Our partnership with Vegenics is a great example of our business model, in which multiple, early-stage partnering agreements will generate a continuing revenue stream to support our own internal development activities,” says Mark Rampy, CBO of CoGenesys.

Previous articleSCCOR Taps BioServe to Ascertain the Genetic Cause of Thoracic Aortic Disease
Next articleNovartis Inks Pact with Adenosine Therapeutics to Develop Drugs for Diabetes and Asthma